The Virtual Biotech

Multi-agent AI framework that mirrors the structure of a human therapeutic research organization — a Chief Scientific Officer agent delegates to domain-specialist scientist agents — to perform end-to-end computational therapeutic discovery across statistical genetics, functional genomics, chemoinformatics, and clinical data.

   
Affiliation Stanford University (Zhang, Eckmann, Miao, Mahon, Zou)
First introduced 2026-02 (bioRxiv 10.64898/2026.02.23.707551, posted 23 February 2026)
Lifecycle stages Multi-stage (hypothesis generation, experiment-design proposals, and analysis across multi-scale therapeutic data)
Autonomy level Semi-autonomous — autonomous trial annotation and analysis with human scientists in the loop
Domain focus Therapeutic discovery and development (target evaluation, trial-outcome analysis, biomarker strategies)
Availability Unknown — preprint describes the framework; no public code release referenced

Approach

The Virtual Biotech organizes a coordinated team of LLM agents using a corporate metaphor. A Chief Scientific Officer (CSO) agent receives a scientific query, delegates it to domain-specialized scientist agents — statistical genetics, functional genomics, pathways and interactions, chemoinformatics, disease biology, and clinical data — and integrates their outputs through data-driven reasoning. Scientist agents leverage complementary tools and knowledge sources spanning multi-omics atlases, single-cell RNA-seq data, pathway databases, chemical/structural resources, and clinical-trial records. The framework supports massive agent parallelism — the clinical-trial study deploys >37,000 “clinical-trialist” agents to autonomously annotate trial outcomes.

Validation

Three translational case studies are reported:

  1. Clinical-trial outcome analysis at scale. >37,000 clinical-trialist agents autonomously annotate outcomes from 55,984 clinical trials, link drug targets to multi-omic features (including cell-type specificity derived from single-cell RNA-seq atlases), and analyze advancement probabilities.
  2. B7-H3 target evaluation in lung cancer. Integrates statistical genetics, single-cell, spatial, and clinicogenomic evidence to propose an antibody–drug conjugate (ADC) strategy while identifying liabilities and differentiation opportunities.
  3. Re-analysis of a terminated OSMRβ ulcerative-colitis trial. Infers potential failure mechanisms and proposes biomarker-guided enrollment strategies addressing precision-medicine gaps.

Notable results

  • Drugs targeting cell-type-specific genes were 40% more likely to advance Phase I → Phase II and 48% more likely to reach Phase IV, with 32% lower adverse event rates — discovered by the trialist-agent fleet across 55,984 trials.
  • End-to-end B7-H3 lung-cancer ADC proposal integrating heterogeneous multi-omics + clinical evidence in a single coordinated agent workflow.
  • Failure-mechanism inference and biomarker-guided enrollment recommendations for a terminated OSMRβ ulcerative-colitis trial.

Primary paper

Zhang, Eckmann, Miao, Mahon, Zou, “The Virtual Biotech: A Multi-Agent AI Framework for Therapeutic Discovery and Development,” bioRxiv 2026.02.23.707551.

Other references

None yet.

Code

Not released at preprint time.